newsfilter
← Latest News
PR Newswire·

RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome

ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture